Fig. 5

Effects of inhibitors/activators of ERK/P65 on ER⁺ BC cells. (a, b, e, and f) MCF-7 and T-47D cells treated with ERK inhibitor PD98059 (10 μM) or lipopolysaccharide (1 μg/ml) as an activator for 7 d were harvested at each time point indicated and subjected to CCK-8 assay (right) and Western blot (left) [*P < 0.05]. (c, d, g, and h) MCF-7 and T-47D cells treated with P65 inhibitor parthenolide (10 μg/ml) or betulinic acid (10 μg/ml) as an activator for 7 d were harvested at each time point indicated and subjected to CCK-8 assay (right) and Western blot (left) [*P < 0.05]